Oxford Biomedica (LON:OXB) Issues Earnings Results

Oxford Biomedica (LON:OXB - Get Free Report) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported GBX (41.75) (($0.55)) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%.

Oxford Biomedica Price Performance

Shares of OXB traded up GBX 10 ($0.13) during midday trading on Monday, reaching GBX 290 ($3.79). The stock had a trading volume of 1,468,327 shares, compared to its average volume of 323,211. The company has a market capitalization of £308.27 million, a P/E ratio of -2.15 and a beta of 1.09. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. The firm's 50 day moving average price is GBX 316.78 and its 200-day moving average price is GBX 378.53. Oxford Biomedica has a 52 week low of GBX 187.83 ($2.46) and a 52 week high of GBX 455 ($5.95).

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.